1-9 Kilograms
$952.10
≥10 Kilograms
$866.10
Our advantages
High quality Letrozole
1.Competitive price
2.Fast Delivery Within 2 days
3.SGS , BV, GMP,ISO approve
4.Professional factory
1.CAS NO: 112809-51-5
2.letrozole Content: 99%
3.Molecular Formula: C17H11N5
4. Molecular Weight: 285.31
5. Appearance white or off-white powder
6. Melting point 181-183 ° C
7. Letrozole is an oral non-steroidal inhibitor for the treatment of hormonally-responsive breast cancer after surgery. letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome p450 unit, the action is specific,and letrozol does not reduce production of mineralo-or corticosteroids.
Letrozole is a new generation aromatase inhibitor, is a synthetic derivative of benzyl triazole, letrozole by inhibiting aromatase, estrogen levels drop, thereby eliminating the stimulating effect of estrogen on tumor growth. Chemotherapy and radiotherapy for breast cancer.
Tests | Specifications | Results |
Appearance | White or off-white crystaline powder | White Crystalline powder |
Solubility
| Soluble in Chloroform; Soluble in ethanol when heated | Conform |
ldentification | (1)Maximum absorption in wavelength of 240 nm Minimum absorption in wavelength of 215 nm | Conform Conform |
(2)Infrared spectrum should be in accordance the dominant peak of contrast | In accordance with the dominant peak of contrast | |
Melting points | 182°C-184°C | 182°C |
Related substances | ≤0.5% | 0.3% |
Single impurity | ≤0.3% | 0.2% |
Loss on drying | ≤1.0% | 0.8% |
[Assay]C17H11N5 (On anhydrous basis) | ≥98.0% | 99.2% |
Conclusion | Conforms Specifications of Enterprise Standard. |
1. Treatment of postmenopausal women with advanced breast cancer (estrogen receptor, progesterone receptor positive or unknown receptor status), used for anti-estrogen therapy after the failure of second-line treatment;
2. For locally advanced or spread after the first-line treatment of postmenopausal breast cancer (foreign data);
3. For the received standard adjuvant tamoxifen therapy in postmenopausal breast cancer after five years of adjuvant therapy in patients with extension (foreign data);
4. Postoperative adjuvant therapy for hormone-positive early breast cancer patients.
Company Information
QingdaoxigemaCHEMICAL Co., Ltd is is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates, food and feed additives, herbal extracts, agrochemicals and fine chemicals etc.
The aim of xigema is a quality policy that "Elements in the system all have been satisfied, Personnel has been trained; Every batch of material is checked, Each procedure guarantees the quality; Every bag of our products is top grade, Service is thoughtful all the time, quality and reputation to increase market share and promote enterprise development. The quality, colors and forms of our products have reached a high level in related chemical industry, which relies on characteristic and advanced processing technology and it has gained a high and reliable reputation from customers at both quality and services.
xigema has become the "Top 500 Chinese manufacturing companies","Top 20 of global agrochemical sales". xigema has 21 subsidiaries and holding companies.
Scan the QR code with your phone, or visit the URL